Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib in Advanced Lung Squamous Cell Carcinoma
NCT03725423Phase 4Unknown
- Sponsor
- Xuzhou Central Hospital
- Start
- Oct 2018
- Primary completion
- Jun 2019
- Modality
- Small Molecules
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in squamous cell carcinoma of the lung (LSCC), sponsored by Xuzhou Central Hospital. Primary endpoint: Response Evaluation Criteria in Solid Tumors at 1 year. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
squamous cell carcinoma of the lung (LSCC)
Beyond the preview
Go deeper on NCT03725423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03725423.